AVT 02

Drug Profile

AVT 02

Alternative Names: AVT-02 UE

Latest Information Update: 30 Nov 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Gottingen
  • Developer DOLTHERA
  • Class Anti-inflammatories; Antipsoriatics; Oligonucleotides
  • Mechanism of Action STAT1 transcription factor inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 31 Mar 2011 Discontinued - Phase-II for Psoriasis in Europe (Topical)
  • 06 Jan 2010 AnGes MG terminates its licence for AVT 02 in respiratory and dermal indications in Asia
  • 10 Oct 2008 Efficacy and adverse events data from a phase IIa trial in Psoriasis released by Avontec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top